Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program

As part of Boehringer Ingelheim Corporation and its United States subsidiaries’ (collectively, “Boehringer Ingelheim”) continued efforts to comply with various applicable state and federal laws and industry guidance documents and best practices, we have developed a comprehensive "U.S. Corporate Compliance Program" (“CCP”). Under California state law, we must annually declare that to the best of our knowledge, and based on our good faith understanding of the statutory requirements, we have established a CCP compliant with requirements of Cal. Health and Safety Code §§ 119400-119402. You may review the description of our CCP by clicking here. Recognizing that compliance is a dynamic concept and program building is an iterative process, we are constantly reviewing Boehringer Ingelheim’s CCP for improvement and will continue to refine the program as necessary throughout each year. Hence, this Annual Declaration is reflective of the Boehringer Ingelheim CCP as of the effective date indicated below. By making this declaration, we are not stating that we can entirely eliminate improper conduct by individual employees, though we have established an effective CCP that consists of policies, procedures and training as further described in our CCP reasonably designed to prevent, detect and remediate violations.

For a hard copy of this Annual Declaration, please send your request to:
Boehringer Ingelheim Pharmaceuticals, Inc.
Office of Ethics & Compliance
P.O. Box 368
Ridgefield, CT 06877-0368
800/243-0127

Fax:  203/798-4408

This page effective: July 1, 2018.